PUBLISHER: Grand View Research | PRODUCT CODE: 1701350
PUBLISHER: Grand View Research | PRODUCT CODE: 1701350
The global RNA targeting small molecule drug discovery market size is estimated to reach USD 5.42 billion by 2030, registering a CAGR of 21.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. RNA-targeting small molecule drug discovery industry continues to undergo rapid growth due to its potential to develop targeted and effective therapeutics for various diseases.
The increasing prevalence of diseases such as cancer, genetic disorders, and viral infections has fueled the demand for RNA-targeting small-molecule drugs. The RNA-targeting small molecule drug discovery industry has grown dramatically as a result of the introduction of cutting-edge technologies like CRISPR-Cas9 and RNA interference. These technologies have made it possible to identify RNA targets that are implicated in the pathogenesis of diseases, which has resulted in the creation of brand-new small-molecule medications that target RNA.
In the upcoming years, the market for RNA targeting small molecules for drug discovery is anticipated to experience significant expansion, driven by the rising expenditure in R&D activities by pharmaceutical and biotechnology businesses. The process of creating innovative, RNA-targeting small molecules is time-consuming and costly, but the potential rewards of focused, efficient treatments make it a worthy investment.
For instance, in 2020 Moderna's recent collaboration with Vertex Pharmaceuticals to develop RNA-targeted small molecule drugs for the treatment of cystic fibrosis is a significant investment in this field. Moderna will use its mRNA technology platform to identify novel RNA targets, while Vertex will apply its expertise in small molecule drug discovery to develop therapies for the targets. This collaboration reflects the growing interest and investment in RNA-targeting small molecule drug discovery, which has the potential to revolutionize disease treatment.